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The scientific response to the HIV pandemic has reached a moment of great promise, but 
also of renewed urgency. Over the last 30 years, basic and clinical sciences have produced an 
armamentarium of highly potent medications and other interventions to treat and prevent HIV 
infection.  When used consistently, antiretroviral therapy can restore a near-normal lifespan for 
persons living with HIV[1] and prevent transmission in persons exposed to HIV [2].  Yet today, only 
around half of persons living with HIV have been tested, accessed treatment and achieved viral 
suppression[3]. Moreover, pre-exposure prophylaxis, medical male circumcision and condoms are 
used only by a fraction of those who could benefit.  Even with robust global and domestic 
investments to address the HIV pandemic, we have not been able to realize the full promise 
offered by these tools to reduce HIV incidence and mortality.  As a result, HIV remains a potent 
public health threat globally, and continues to demand urgent prioritization.     
Failure to achieve maximum public health impact with the efficacious interventions 
available is not, however, unique to the field of HIV.  Americans receive approximately 50% of 
indicated care across a spectrum of conditions; globally this figure is far lower, even when costs 
are not prohibitive[4].  Awareness of this alarming chasm has motivated the development and 
growth of the field of implementation research (IR).  IR strives to achieve scientific objectives 
shared by all fields: creating generalizable, transparent, public and rigorous knowledge. IR, 
however, also emphasizes key and distinctive perspectives and has introduced substantive 
innovations to address implementation problems.  IR, for example, seeks not just the right answer, 
but also the right questions through stakeholder engagement and participatory research; 
considers public health impact in the appraisal of science (e.g., the REAIM[5]); attempts to find 
optimal balance between external as well as internal validity; offers novel frameworks to organize 
the dizzying complexity of drivers of implementation (e.g., Consolidated Framework for 
Implementation Research[6]); incorporates theories to explain behaviour of systems and people 
(e.g., normalisation process theory[7]); specifies reporting requirements in implementation 
research (e.g., STARI[8]); proposes novel study designs (e.g., hybrid designs[9]) and has created 
new streams of discourse (e.g., the journal Implementation Science and dedicated scientific 
meetings).   
The encounter between the scientific response to HIV and the rapidly growing field of 
implementation research creates a unique opportunity – but one that we must collectively and 
urgently exploit. The HIV field has a long-standing and successful research agenda to understand 
behaviors associated with HIV acquisition and transmission as well as a robust literature on health 
behaviours.  Perspectives from implementation research, however, can enrich and accelerate 
progress made to date – both by linking to similar challenges in other health fields as well as 
through original perspectives. Yet, while the HIV research community broadly recognizes that 
gaps in implementation stand in the way of greater public health progress, neither full commitment 
to implementation science nor consensus about the field’s foundational perspectives are firmly 
established.  Some, who don’t doubt the importance of implementation nor the power of science, 
remain sceptical of a “science of implementation” and the contextual and behavioural inquiry 
implied.  Others who recognize the need for a “science of implementation” in the HIV response 
may find the emphasis on interdisciplinary, stakeholder-engaged processes, use of 
implementation theories and frameworks, importance of external validity, and the value of fit and 
reach with health systems unconvincing.   To be most effective, both a strong cadre of individuals 
carrying out implementation research, as well as a community that scientifically supports, elevates 
and invests in this area is needed.     
In September of 2018, we issued an open call as well as invited submissions on HIV-related 
implementation research with attention to featuring methodological innovations.  The resulting 
collection offers a window into the leading edge of HIV implementation science today and, we 
hope, will also help propel our collective engagement with IR forward. 
One set of papers in this supplement presents perspectives on the HIV response from 
traditions in the social sciences, with the promise of catalyzing deeper cross-disciplinary dialogue.  
Theories and frameworks such as the Consolidated Framework for Implementation Research 
which are widely used in IR draw from a range of underlying disciplines and traditions, and this 
series of papers highlights those perspectives. Jacob Bor and Harsha Thirumurthy, both 
economists, observe that humans are not health maximisers, but rather utility (or happiness) 
maximisers – a central tenant of economics – and explores implications of this observation on 
research addressing the HIV epidemic.   Highlighting methods used in marketing, Alexandra 
Minnis and colleagues describe the use of discrete choice experiments to quantify preferences of 
women for different attributes of female-controlled HIV prevention products, which can inform 
designs which facilitate adoption and sustained use.  An anthropologist by training, Norma Ware 
uses ethnography to offer novel conceptualizations about how health care workers and patients 
experience the implementation of evidence-based HIV services – thus opening the door to 
innovations in service delivery.  Using work from Zambia, Laura Beres and colleagues review 
human centred design – in which researchers and end-users co-create knowledge – to enhance 
the uptake of innovations for HIV treatment and prevention.  Guy Harling and colleagues explores 
sociological perspectives and tools used to understand the HIV response, with an emphasis on 
social networks.  Citing work in China, Dan Wu and colleagues summarize the utility of crowd 
sourcing to better meet the sexual health needs of underserved populations.  Finally, Anjuli 
Wagner and colleagues draws from systems engineering to describe a package of activities that 
systematically identify service delivery gaps.  Overall, we hope these papers will act as “gateway” 
for further dialogue between investigators working on HIV and diverse disciplinary traditions.   
Another set of papers in this volume offer theoretical or practical guidance for the conduct of 
implementation research addressing HIV.  Megha Mehrotra and colleagues formalize the often-
invoked concept of context – using differentiated service delivery models as an example -- through 
applying Pearl and Bareinboim’s transport framework, thus linking a conceptual understanding of 
“context” with epidemiolocal tools to address context.  James Hargreaves and colleagues address 
five critical challenges to trials asking implementation questions.  Several papers describe 
methods or approaches for conduct of IR with vulnerable and under-reached populations.  
Christian Grov and colleagues describe internet-only cohorts to reach and follow MSM that would 
otherwise may not participate in research.  Sheree Schwartz and colleagues use the Consolidated 
Framework for Implementation Research (CFIR) to assess research in key populations that 
require cognizance of stigma, criminalization and other forms of discrimination.  Joshua Solomon 
presents a novel approach, called comparative strategy, to advance the use of data on costs into 
IR. Jennifer Stewart and colleagues have led cutting edge work with the faith-based community 
to address HIV prevention for African American women, and in this supplement, they lay out best 
practices in public health and IR with religious leaders to best leverage a crucial and underused 
source of social influence. Laura Packel and colleagues present a series of studies that trace the 
evolution of research agenda around incentives for engagement in HIV care from efficacy to 
effectiveness and to implementation.  This set of papers provide a map for new pathways in the 
conduct of IR in the HIV response.  
Finally, a number of submissions describe real-world implementation of activities to address 
the HIV epidemic thorough the lens of implementation research, which represent case studies 
“learning while doing.” Susan Buchbinder and Diane Havlir describe San Francisco’s multisector 
HIV response based on the collective impact theory that has driven HIV incidence and mortality 
to historical lows.   Maira Sohail and colleagues outline the formation of a network of health care 
facilities in Alabama to engage in both quality improvement and research activities – illustrating 
the creation of a practice-based research platform that promises to generate data highly relevant 
to routine practice settings in the US South.  Geri Donenberg and colleagues from Rwanda 
describe implementing and evaluating HIV services for adolescents using the EPIS framework 
and demonstrate how application of a framework from IR can strengthen evaluation.  From 
Washington State, Julia Dombrowski, who holds positions in both a service delivery agency as 
well as in academia, argue that that the involvement of public health agencies as producers as 
well as consumers of IR can elevates the relevance and rigor of research.  Industry, an important 
partner in the HIV response, is rarely included in the implementation dialogue. D Allen Roberts 
and colleagues examine cost and cost effectiveness of innovative models of HIV service delivery. 
Here, Maggie Czarnogorski contributes a perspective from ViiV and articulates the role that ViiV 
can play in promoting IR, especially at this moment in order to make the most of long-acting 
injectable medications which are on the cusp of reaching market.   Delivette Castor led 
investments in IR from the United States Agency for International Development (USAID) and the 
President’s Emergency Plan for AIDS Relief (PEPFAR), and with colleagues in this supplement, 
offers an appraisal of the public health impacts of research investments.    
As Robert Eisinger, Carl Dieffenbach and Anthony Fauci describe in the opening piece of the 
supplement, the scientific response to HIV has made a remarkable journey to date, but one that 
we must complete through implementation research.  Approximately 30 years ago, AIDS was a 
little understood and greatly feared mystery illness.  Today, we have a detailed molecular 
understanding of the HIV virus and its pathophysiology.  We have dozens of medications and 
other interventions to treat and prevent HIV, all tested through rigorous studies.  We have a robust 
understanding of the economic, social and psychological drivers of the epidemic.  Given these 
successes, tomorrow’s critical scientific questions naturally turn to addressing implementation.   
To do so effectively, the research community must pivot to strengthen the skills, teams and tools 
needed to carry out research on the behaviour of systems, organizations, health care workers, as 
well as patients and communities.  We hope this collection offers a window onto both the current 
practice of IR as well as future aspirations to reach the destination of bringing this pandemic to a 
close.        
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